Penneo

Nordic Solar A/S har her til morgen aflagt Q1 2023 regnskab. Insider salg i Scandinavian Medical Solutions. Bawat A/S offentliggjorde i tirsdags deres resultater for første kvartal 2023. Vi har netop offentliggjort vores opdaterede SaaS rapport. Hansa Biopharma’s vigtige partner inden for genterapiområdet, Sarepta Therapeutics, måtte i går gennem endnu en kursmæssig rutsjetur. Curasight har her til morgen aflagt regnskab for 1. kvartal.

From a valuation perspective, the sector has been hit by a higher interest rate environment, which potentially could have peaked. At the same time, we have seen a lower growth rate in Q1 2023 from the listed global SaaS companies, which is now closer to Gartner's projected 2023 SaaS global market growth.

Earlier today, Penneo was represented by the company's CEO Christian Stendevad and CFO Casper Nielsen Christiansen. They presented the Q1 financial results, provided an update on the recent news, and answered the questions from the audience.

Penneo released its Q1 2023 report this morning, maintaining its 2023 full-year guidance. By the end of Q1 2023, Penneo's ARR increased to DKK 74.2m, corresponding to 27% YoY growth.

ExpreS2ion Biotechnologies har her til morgen aflagt 1. kvartalsregnskab. Penneo A/S er her til morgen ude med regnskab for første kvartal 2023. Scandinavian Medical Solutions er her til morgen ude med halvårsrapporten for regnskabsåret 2022/2023. Odico A/S melder her til morgen om et nyt pilotprojekt mellem Odico A/S og Arkil. Bavarian Nordic: Interview med Head of IR Rolf S. Sørensen.

Skjern Bank har her fra morgenstunden offentliggjort sit regnskab for 1. kvartal 2023. Impero - Compliance. Simplified. melder her til morgen i Q1 regnskabet, at selskabet vokser ARR med 40% YoY. Ascelia Pharma AB har her til morgen offentliggjort regnskab for 1. kvartal 2023. Hansa Biopharma kan potentielt modtage op til ca. USD 400 millioner i royalties og milestone-betalinger. Penneo A/S annoncerede i går, at Kirstine Møller Pedersen tiltræder som selskabets nye Chief Marketing Officer.

Our third monthly Software-as-a-Service (SaaS) newsletter is out! In our newsletter, we shed light on the recent market development and the current trend of companies being taken off the stock market (takeover and delistings).

Today, we have sent out our second monthly Software-as-a-Service (SaaS) newsletter, which covers news from March month and the recent development in the ARR valuation multiple. This newsletter’s theme focuses on the growth outlook for 2023, providing perspectives from Gartner reports, a CIO survey, as well as new 2023 guidance from the listed companies. Looking into the Danish SaaS sector, we see that the expected 2023 growth rates (we take the midrange of the SaaS companies’ 2023 ARR guidance) are slightly above the realized ARR growth from 2022.

Last week, we hosted a Software-as-a-Service (SaaS) deep dive event, focusing on the market outlook for 2023 and market drivers. In the introduction, we set the scene and provided an update on the current investor topics in the SaaS sector followed by projected overall software market growth rates in 2023 and valuation perspectives.

BioPorto A/S har her til morgen offentliggjort regnskab for 2022. Hansa Biopharma annoncerede, at der nu er indgået aftale i Spanien om refusion vedrørende selskabets Idefirix produkt. kursmål på Danske Bank hævet til DKK 150. Roblon A/S afholder event i dag kl. 14. I dag fra kl. 09:30 til 11.30 afholder vi et SaaS Deep Dive event med fokus på outlook for 2023. InDex Pharmaceuticals AB - interview with CEO Jenny Sundqvist and CDO Eva Arlander.